Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.

about

The proteasome and proteasome inhibitors in multiple myeloma.Precision oncology: neither a silver bullet nor a dream.

P2860

Q47339695-779DFE60-CC9C-478F-A7C0-2D447A53E9E3 Q47737073-2A2DEC19-5967-4176-9163-FAA3FDDF2133

P2860

Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.

Item

http://www.wikidata.org/entity/Q39044362

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.

@en

Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.

@nl

type

Item

label

Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.

@en

Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.

@nl

prefLabel

Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.

@en

Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.

@nl

P1476

Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.

@en

P2093

Evangelos Terpos

http://www.w3.org/2001/XMLSchema#string

Maria Gavriatopoulou

http://www.w3.org/2001/XMLSchema#string

P2860

Waldenström macroglobulinemia

Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

Ibrutinib in previously treated Waldenström's macroglobulinemia.

Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations

Diagnosis and management of Waldenstrom's macroglobulinemia

Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia

The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia

How I treat Waldenström macroglobulinemia

microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia

P304

197-205

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13543784.2017.1275561

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

Efstathios Kastritis

P577

2017-01-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28043164

http://www.w3.org/2001/XMLSchema#string

Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.

about

P2860

P2860

Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698